Skip to main content
๐ŸงฌPeptide Protocol Wiki

IGF-1 LR3: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 80 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides โ†’

โœ“Reviewed byEditorial Team
๐Ÿ“…Updated February 16, 2026
Unverified

๐Ÿ“ŒTL;DR

  • โ€ข4 community protocols documented
  • โ€ขEvidence level: Anecdotal Reports
  • โ€ขBased on 80 community reports
  • โ€ข3 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

AspectClinical ApproachCommunity ApproachSignificance
Route of AdministrationIGF-1 LR3 is primarily used as a cell culture supplement in research settings. Limited in vivo studies use IV or SubQ administration in animal models.Community uses both subcutaneous (systemic) and intramuscular (site-specific) injection. IM injection into trained muscles is popular based on the belief that localized IGF-1 promotes site-specific growth.high

Site-specific IM injection for localized hypertrophy is a community concept with limited scientific support. IGF-1 LR3 has a long half-life and distributes systemically regardless of injection site.

Dose RangeCell culture applications use nanogram concentrations. In vivo animal studies use weight-based dosing in the mcg/kg range. No human clinical studies have established therapeutic doses.Community uses fixed doses of 20-100 mcg daily. The dose range has been established entirely through community self-experimentation.high

All community dosing is derived from anecdotal experience rather than clinical dose-finding studies. There is no validated human dosing data for IGF-1 LR3.

Hypoglycemia RiskIGF-1 analogs are known to lower blood glucose through insulin-like activity. Native IGF-1 (mecasermin) carries FDA-labeled hypoglycemia warnings.Community is aware of hypoglycemia risk and recommends having fast-acting carbohydrates available during use. Some users time injections with post-workout meals to mitigate blood sugar drops.high

Hypoglycemia is a serious risk with IGF-1 analogs. Community awareness is generally good but the lack of medical supervision increases risk.

Compare these community approaches with published research findings.

Community Protocols

Standard Muscle Growth Protocol

Popular
Route
Subcutaneous or Intramuscular
Dose
20-50 mcg
Frequency
Once daily on training days
Duration
4-6 weeks

Injected post-workout bilaterally into trained muscle groups or subcutaneously. Strict 4-6 week cycles to prevent desensitization.

Conservative/Beginner Protocol

Common
Route
Subcutaneous
Dose
20-40 mcg
Frequency
Once daily
Duration
4 weeks

Lower-dose SubQ protocol for first-time users; start at 20 mcg and titrate up based on tolerance

Advanced Bodybuilding Protocol

Niche
Route
Intramuscular (site-specific)
Dose
50-100 mcg
Frequency
Once daily post-workout
Duration
4-6 weeks

Higher-dose protocol split across 2-4 muscle groups post-workout. Carries higher hypoglycemia risk.

10-Day Alternating MGF/IGF-1 LR3 Protocol

Niche
Route
Intramuscular
Dose
40-50 mcg IGF-1 LR3 on alternating days
Frequency
Every other day (alternating with MGF)
Duration
10-20 days per cycle

Alternates IGF-1 LR3 and MGF to target different phases of muscle repair and satellite cell activation

Stacking Patterns

IGF-1 LR3 + HGH

Common

Combines exogenous GH with direct IGF-1 receptor activation for enhanced anabolic effects; considered advanced due to complexity

igf-1-lr3hgh-191aa

IGF-1 LR3 + MGF Alternating Protocol

Niche

Alternates between IGF-1 LR3 (growth and differentiation) and MGF (satellite cell activation) to target different phases of muscle repair

igf-1-lr3mgf

IGF-1 LR3 + PEG-MGF

Niche

Combined growth factor approach; PEG-MGF for sustained satellite cell activation and IGF-1 LR3 for potent IGF-1R signaling

igf-1-lr3peg-mgf

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 80+ self-experimenters report. Free with email.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Sources

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.

IGF-1 LR3 is a potent growth factor used in the bodybuilding and performance community for its anabolic effects. Unlike GH secretagogues which stimulate endogenous GH production, IGF-1 LR3 directly activates IGF-1 receptors with enhanced potency due to its reduced IGFBP binding.

Understanding Protocol Divergence#

No Human Clinical Data#

A critical distinction for IGF-1 LR3 is that it has no human clinical trial data. All community dosing, cycling, and administration practices are derived from self-experimentation. The compound is primarily manufactured as a cell culture supplement, and community use represents a significant departure from its intended application.

Site-Specific Injection#

The community practice of injecting IGF-1 LR3 intramuscularly into recently trained muscles is based on the belief that localized delivery enhances site-specific hypertrophy. However, given IGF-1 LR3's extended half-life (~20 hours), the peptide distributes systemically regardless of injection site, making the site-specific growth concept questionable.

Commonly Reported Outcomes#

Community members frequently report the following when using IGF-1 LR3:

  • Muscle fullness: Increased muscle pumps and fullness during training
  • Recovery: Enhanced recovery between training sessions
  • Strength gains: Modest strength improvements during cycles
  • Hypoglycemia: Some users report blood sugar drops, especially at higher doses
  • Gut distention: A concern at higher doses or prolonged use, related to smooth muscle growth

Important Caveats#

  • No human clinical data exists for IGF-1 LR3
  • Hypoglycemia is a serious potential side effect requiring monitoring
  • Long-term effects of exogenous IGF-1 receptor activation are unknown
  • Product quality varies significantly between suppliers
  • High-dose or prolonged use carries theoretical organ growth risks

Reconstitution and Storage Practices#

  • Reconstitution: 0.6% acetic acid or bacteriostatic water per 1 mg vial
  • Storage: Refrigerated at 2-8 degrees C; very sensitive to temperature
  • Shelf life: Use within 2-3 weeks of reconstitution
  • Note: IGF-1 LR3 is more fragile than many peptides; avoid vigorous shaking during reconstitution

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Frequently Asked Questions About IGF-1 LR3

Explore Further

โš ๏ธ

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.